A study of MGC018 in сombination with MGD019 in participants with advanced solid tumors

The company MacroGenics is enrolling patients into the clinical trial investigating A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors.

Study CP-MGC018-02 is a study of MGC018 in combination with lorigerlimab. The study is designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including mCRPC, melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled. MGC018 and lorigerlimab are administered separately on Day 1 of every 3-week (21-day) cycle at the assigned dose for each cohort. Participants who do not meet criteria for study drug discontinuation may receive study drugs for up to a total of 35 cycles (approximately 2 years). Tumor assessments are performed every 6 weeks for the initial 6 months on study drugs, then every 12 weeks (± 21 days) until progressive disease (PD). Participants will be followed for safety throughout the study. 

The study start date is March 2022.

This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05293496.